Keymed and Lepu Biopharma Enter into an Exclusive License Agreement with AstraZeneca for CMG901 to Treat Claudin 18.2-Positive Solid Tumors
- KYM Biosciences, the joint venture established by Keymed & Lepu Biopharma will receive $63M up front, ~$1.1B in additional development and sales-related milestones along with royalties. The transaction is expected to be close in H1’23
- AstraZeneca will lead the research, development, manufacture & commercialization of CMG901 globally. CMG901 is being studied in the P-I trial for Claudin 18.2+ solid tumors incl. gastric cancers
- CMG901 showed a favorable safety & tolerability profile with an encouraging anti-tumor efficacy across the dose levels tested in the preliminary results from the P-I trial. CMG901 improves AstraZeneca's ADC pipeline & aids in improving gastrointestinal cancer patients' treatment options & outcomes
Ref: PRNewswire | Image: Keymed
Related Post:- AstraZeneca’s Imfinzi (durvalumab) + Imjudo (tremelimumab) Receives EU Approval for Advanced Liver and Non-Small Cell Lung Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].